Drugs Made In America Acquisition II Corp. (DMII)
NASDAQ: DMIIFinancial ServicesShell CompaniesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
DMII stock chart
Technical analysisKey statistics
All statistics- Market cap
- $649.10M
- P/E (TTM)
- 33.97
- EPS (TTM)
- $0.30
- Dividend yield
- None
- 52-week range
- 9.86 – 10.33
- Day range
- 10.18 – 10.20
- Volume / Avg
- 120.55K / 53.22K
- Beta
- —
- Shares outstanding
- 63.70M
52-week range
DMII stock today
On Oct 7, DMII ended the session at $10.19, adding $0.005 (0.05%), versus the S&P 500's 0.22% decline. Volume was 2.3x the average at 120.55K shares, a sign of unusually heavy trading. Shares are 1.4% below their 52-week high of $10.33 and 3.3% above the 52-week low of $9.86, in the middle of the past year's range.
At 34.0x trailing earnings, Drugs Made In America Acquisition II trades in line with the peer-group median of 34.4x.
Summary generated from market data by MetaCap's automated system. Methodology
About Drugs Made In America Acquisition II
Company profileDrugs Made In America Acquisition II Corp. does not have significant operations. The company focuses on effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or other similar business combination with one or more businesses.
- Sector
- Financial Services
- Industry
- Shell Companies
- CEO
- Mr. Roger Bendelac
- Headquarters
- New York, NY
- IPO year
- 2025
Drugs Made In America Acquisition II peers
Financial Services sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| CCXIChurchill Capital Corp XI Class A | 11.24 | -5.74% | $626.07M | vs DMII |
| EVACEQV Ventures Acquisition Corp. II Class A | 10.31 | -0.10% | $602.60M | vs DMII |
| BCSSBain Capital GSS Investment Corp. Class A | 10.22 | -0.10% | $596.85M | vs DMII |
| CXIIChurchill Capital Corp XII Class A | 10.65 | 0.00% | $591.61M | vs DMII |
| CEPFCantor Equity Partners IV Inc. Class A | 10.27 | -0.19% | $586.93M | vs DMII |
| AEXAAmerican Exceptionalism Acquisition Corp. A Class A | 10.85 | -0.64% | $536.65M | vs DMII |
| XRPNArmada Acquisition Corp. II Class A | 25.01 | +30.26% | $790.07M | vs DMII |
| NWAXNew America Acquisition I Corp. Class A | 10.05 | -0.05% | $500.24M | vs DMII |
Indexes, lists and sector
Largest Financial Services stocks
Drugs Made In America Acquisition II stock FAQ
What is Drugs Made In America Acquisition II's stock price today?
DMII last traded at $10.19 as of Oct 7, 4:00 PM EDT, up 0.05% on the day. Prices are delayed at least 15 minutes.
What is DMII's P/E ratio?
DMII trades at a trailing P/E ratio of 33.97, compared with a median of 34.4 for its closest peers.
Who is Drugs Made In America Acquisition II's CEO?
Mr. Roger Bendelac is the chief executive officer of Drugs Made In America Acquisition II Corp..
What is the DMII 52-week high?
The 52-week high for DMII is $10.33 and the 52-week low is $9.86. The stock is currently 1.4% below its high.